Multiplexed immunofluorescence identifies high stromal CD68+PD-L1+ macrophages as a predictor of improved survival in triple negative breast cancer.
- Publisher:
- Springer Science and Business Media LLC
- Publication Type:
- Journal Article
- Citation:
- Sci Rep, 2021, 11, (1), pp. 21608
- Issue Date:
- 2021-11-03
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, J | |
dc.contributor.author | Browne, L | |
dc.contributor.author | Slapetova, I | |
dc.contributor.author | Shang, F | |
dc.contributor.author | Lee, K | |
dc.contributor.author | Lynch, J | |
dc.contributor.author | Beretov, J | |
dc.contributor.author | Whan, R | |
dc.contributor.author | Graham, PH | |
dc.contributor.author | Millar, EKA | |
dc.date.accessioned | 2022-05-16T06:57:40Z | |
dc.date.available | 2021-10-15 | |
dc.date.available | 2022-05-16T06:57:40Z | |
dc.date.issued | 2021-11-03 | |
dc.identifier.citation | Sci Rep, 2021, 11, (1), pp. 21608 | |
dc.identifier.issn | 2045-2322 | |
dc.identifier.issn | 2045-2322 | |
dc.identifier.uri | http://hdl.handle.net/10453/157426 | |
dc.description.abstract | Triple negative breast cancer (TNBC) comprises 10-15% of all breast cancers and has a poor prognosis with a high risk of recurrence within 5 years. PD-L1 is an important biomarker for patient selection for immunotherapy but its cellular expression and co-localization within the tumour immune microenvironment and associated prognostic value is not well defined. We aimed to characterise the phenotypes of immune cells expressing PD-L1 and determine their association with overall survival (OS) and breast cancer-specific survival (BCSS). Using tissue microarrays from a retrospective cohort of TNBC patients from St George Hospital, Sydney (n = 244), multiplexed immunofluorescence (mIF) was used to assess staining for CD3, CD8, CD20, CD68, PD-1, PD-L1, FOXP3 and pan-cytokeratin on the Vectra Polaris™ platform and analysed using QuPath. Cox multivariate analyses showed high CD68+PD-L1+ stromal cell counts were associated with improved prognosis for OS (HR 0.56, 95% CI 0.33-0.95, p = 0.030) and BCSS (HR 0.47, 95% CI 0.25-0.88, p = 0.018) in the whole cohort and in patients receiving chemotherapy, improving incrementally upon the predictive value of PD-L1+ alone for BCSS. These data suggest that CD68+PD-L1+ status can provide clinically useful prognostic information to identify sub-groups of patients with good or poor prognosis and guide treatment decisions in TNBC. | |
dc.format | Electronic | |
dc.language | eng | |
dc.publisher | Springer Science and Business Media LLC | |
dc.relation.ispartof | Sci Rep | |
dc.relation.isbasedon | 10.1038/s41598-021-01116-6 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Antigens, CD | |
dc.subject.mesh | Antigens, Differentiation, Myelomonocytic | |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | B7-H1 Antigen | |
dc.subject.mesh | Biomarkers, Tumor | |
dc.subject.mesh | Female | |
dc.subject.mesh | Fluorescent Antibody Technique | |
dc.subject.mesh | Follow-Up Studies | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Lymphocytes, Tumor-Infiltrating | |
dc.subject.mesh | Macrophages | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Prognosis | |
dc.subject.mesh | Retrospective Studies | |
dc.subject.mesh | Stromal Cells | |
dc.subject.mesh | Survival Rate | |
dc.subject.mesh | Triple Negative Breast Neoplasms | |
dc.subject.mesh | Tumor Microenvironment | |
dc.subject.mesh | Lymphocytes, Tumor-Infiltrating | |
dc.subject.mesh | Macrophages | |
dc.subject.mesh | Stromal Cells | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | Antigens, CD | |
dc.subject.mesh | Antigens, Differentiation, Myelomonocytic | |
dc.subject.mesh | Fluorescent Antibody Technique | |
dc.subject.mesh | Prognosis | |
dc.subject.mesh | Survival Rate | |
dc.subject.mesh | Retrospective Studies | |
dc.subject.mesh | Follow-Up Studies | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Female | |
dc.subject.mesh | Tumor Microenvironment | |
dc.subject.mesh | Triple Negative Breast Neoplasms | |
dc.subject.mesh | Biomarkers, Tumor | |
dc.subject.mesh | B7-H1 Antigen | |
dc.title | Multiplexed immunofluorescence identifies high stromal CD68+PD-L1+ macrophages as a predictor of improved survival in triple negative breast cancer. | |
dc.type | Journal Article | |
utslib.citation.volume | 11 | |
utslib.location.activity | England | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science/School of Mathematical and Physical Sciences | |
utslib.copyright.status | open_access | * |
dc.date.updated | 2022-05-16T06:57:35Z | |
pubs.issue | 1 | |
pubs.publication-status | Published online | |
pubs.volume | 11 | |
utslib.citation.issue | 1 |
Abstract:
Triple negative breast cancer (TNBC) comprises 10-15% of all breast cancers and has a poor prognosis with a high risk of recurrence within 5 years. PD-L1 is an important biomarker for patient selection for immunotherapy but its cellular expression and co-localization within the tumour immune microenvironment and associated prognostic value is not well defined. We aimed to characterise the phenotypes of immune cells expressing PD-L1 and determine their association with overall survival (OS) and breast cancer-specific survival (BCSS). Using tissue microarrays from a retrospective cohort of TNBC patients from St George Hospital, Sydney (n = 244), multiplexed immunofluorescence (mIF) was used to assess staining for CD3, CD8, CD20, CD68, PD-1, PD-L1, FOXP3 and pan-cytokeratin on the Vectra Polaris™ platform and analysed using QuPath. Cox multivariate analyses showed high CD68+PD-L1+ stromal cell counts were associated with improved prognosis for OS (HR 0.56, 95% CI 0.33-0.95, p = 0.030) and BCSS (HR 0.47, 95% CI 0.25-0.88, p = 0.018) in the whole cohort and in patients receiving chemotherapy, improving incrementally upon the predictive value of PD-L1+ alone for BCSS. These data suggest that CD68+PD-L1+ status can provide clinically useful prognostic information to identify sub-groups of patients with good or poor prognosis and guide treatment decisions in TNBC.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph